cyc 202 has been researched along with Focal Segmental Glomerulosclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haylor, J; Khwaja, A; Nutter, F | 1 |
| Barnett, A; Chu, TH; D'Agati, V; Gelman, IH; Gherardi, D; Gianella-Borradori, A; Nelson, PJ | 1 |
2 other study(ies) available for cyc 202 and Focal Segmental Glomerulosclerosis
| Article | Year |
|---|---|
Seliciclib inhibits renal hypertrophy but not fibrosis in the rat following subtotal nephrectomy.
Topics: Albuminuria; Animals; Cyclin A1; Cyclin-Dependent Kinase 2; Disease Progression; Extracellular Matrix; Fibrosis; Glomerulosclerosis, Focal Segmental; Hypertension; Hypertrophy; Kidney; Nephrectomy; Purines; Rats; Rats, Wistar; Renal Insufficiency, Chronic; Roscovitine | 2012 |
Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202.
Topics: Animals; Cyclin-Dependent Kinases; Disease Models, Animal; Dose-Response Relationship, Drug; Glomerulosclerosis, Focal Segmental; Kidney; Mice; Mice, Transgenic; Purines; Roscovitine | 2004 |